Most Read Articles
1
Issue 1760 · August 3, 2026
Bemotrizinol — A New Sunscreen
Med Lett Drugs Ther. 2026 Aug 3; 68(1760):121-2 doi:10.58347/tml.2026.1760a
Bemotrizinol (bis-ethylhexyloxyphenol methoxyphenol triazine), a broad-spectrum, organic ultraviolet (UV) filter that has been available in Europe since 2000, is the first new active ingredient with broad availability to be added to the FDA's OTC sunscreen monograph in more than 25 years, and the first organic UV filter to be generally recognized as safe and effective (GRASE). Data with other organic UV filters are insufficient for a GRASE designation.
2
Issue 1760 · August 3, 2026
Mitapivat (Aqvesme) for Thalassemia
Med Lett Drugs Ther. 2026 Aug 3; 68(1760):124-6 doi:10.58347/tml.2026.1760c
Mitapivat ( Aqvesme – Agios), an oral pyruvate kinase activator, has been approved by the FDA for treatment of anemia in adults with alpha or beta thalassemia. It is the first product to be approved in the US for treatment of alpha thalassemia and the first oral option for beta thalassemia. Mitapivat was approved in 2022 as Pyrukind for treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
3
Issue 1760 · August 3, 2026
Icotrokinra (Icotyde) for Psoriasis
Med Lett Drugs Ther. 2026 Aug 3; 68(1760):122-4 doi:10.58347/tml.2026.1760b
The FDA has approved the oral interleukin (IL)-23 receptor antagonist icotrokinra ( Icotyde – Janssen) for treatment of moderate to severe plaque psoriasis in patients ≥12 years old who are candidates for systemic treatment or phototherapy. Icotrokinra is the first oral targeted interleukin blocker to become available in the US.
4
Issue 1760 · August 3, 2026
Sibeprenlimab (Voyxact) for Primary Immunoglobulin A Nephropathy
Med Lett Drugs Ther. 2026 Aug 3; 68(1760):126-7 doi:10.58347/tml.2026.1760d
Sibeprenlimab ( Voyxact – Otsuka), a subcutaneously injected cytokine A proliferation-inducing ligand (APRIL) blocker, has been granted accelerated approval by the FDA to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk for disease progression. Sibeprenlimab is the first APRIL blocker to be approved in the US. Atacicept (Trutakna) , a B-lymphocyte stimulator and APRIL blocker, was recently granted accelerated FDA approval for the same indication; it will be reviewed in a future issue.
5
Issue 1759 · July 20, 2026 Free
Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19
Med Lett Drugs Ther. 2026 Jul 20; 68(1759):113-4 doi:10.58347/tml.2026.1759a
The FDA has approved ensitrelvir ( Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis of COVID-19 in patients ≥12 years old who had contact with an infected individual. Ensitrelvir is the first oral antiviral drug to be approved in the US for this indication. The parenteral monoclonal antibody combinations bamlanivimab and etesevimab and casirivimab and imdevimab (REGEN-COV) are no longer authorized for postexposure prophylaxis of COVID-19 in the US.
6
Issue 1760 · August 3, 2026
Inqovi for Acute Myeloid Leukemia (online only)
Med Lett Drugs Ther. 2026 Aug 3; 68(1760):e127-8 doi:10.58347/tml.2026.1760e
The FDA has approved Inqovi (Taiho Oncology), a fixed-dose combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine, for use in combination with venetoclax ( Venclexta , and generics) for oral treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are ≥75 years old or who have comorbidities that prevent use of intensive induction chemotherapy. The combination was approved in 2020 for treatment of myelodysplastic syndromes (MDS). IV decitabine or azacitidine plus oral venetoclax has been used for treatment of newly diagnosed AML for years.
7
Issue 1759 · July 20, 2026 Free
In Brief: New Warning for OTC Orlistat (Alli)
Med Lett Drugs Ther. 2026 Jul 20; 68(1759):116 doi:10.58347/tml.2026.1759c
The FDA now requires a warning about a risk of acute kidney injury in the product label for the 60-mg capsules of the pancreatic and gastric lipase inhibitor orlistat, which are available over the counter as Alli for weight loss.1 The label for the 120-mg capsules, which are available by prescription as Xenical , already includes a warning about a risk of oxalate nephrolithiasis and oxalate nephropathy (orlistat increases oxalate absorption).
8
Issue 1759 · July 20, 2026 Free
OTC Differin Epiduo Gel for Acne
Med Lett Drugs Ther. 2026 Jul 20; 68(1759):116 doi:10.58347/tml.2026.1759d
Differin Epiduo gel (Galderma), a fixed-dose combination of the synthetic retinoid adapalene 0.1% and the oxidizing agent benzoyl peroxide 2.5%, is now available over the counter (OTC) for topical treatment of acne in patients ≥12 years old. It will remain available by prescription for use in patients 9-11 years old. A gel containing adapalene 0.3% and benzoyl peroxide 2.5% ( Epiduo Forte , and generics) is available by prescription for use in patients ≥12 years old.
9
Issue 1759 · July 20, 2026
Drugs for Hypertriglyceridemia
Med Lett Drugs Ther. 2026 Jul 20; 68(1759):117-9 doi:10.58347/tml.2026.1759e
Adults with persistent fasting triglyceride levels ≥150 mg/dL are considered to have hypertriglyceridemia; when levels are ≥500 mg/dL, it is considered severe. Hypertriglyceridemia is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD); severe hypertriglyceridemia increases the risk of acute pancreatitis.
10
Issue 1759 · July 20, 2026
Omidenepag Isopropyl (Omlonti) for Glaucoma
Med Lett Drugs Ther. 2026 Jul 20; 68(1759):114-6 doi:10.58347/tml.2026.1759b
The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP 2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omidenepag is the first selective prostaglandin EP 2 receptor agonist to be approved in the US. It has been available in Japan since 2018.